AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
01 5월 2024 - 10:00PM
Business Wire
AbCellera (Nasdaq: ABCL), Viking Global Investors (“Viking”),
and ArrowMark Partners (“ArrowMark”) announced today that they have
entered into a collaboration to advance new antibody drug programs
with an aim to launch multiple asset-based companies. The first two
programs will be in the area of immunology.
The collaboration brings together Viking and ArrowMark’s
expertise in early-stage investing and company creation with
AbCellera’s engine for discovering and developing antibody
medicines. Under the collaboration, ArrowMark and Viking will lead
the initial process of program selection, followed by joint
determination of the therapeutic product profile and AbCellera’s
initiation of new antibody drug programs. AbCellera will advance
programs to development candidates and has an option to conduct
cGMP manufacturing to support Phase 1 clinical trials. Successful
programs will be further developed through the creation of Newcos,
with Viking and ArrowMark funding work through to company
launch.
“The next generation of drug targets requires the best
technology to unlock their potential. We aim to address the
significant unmet medical need in the lives of patients struggling
with autoimmune disorders and other diseases,” said Tony Yao, M.D.,
Ph.D., Life Science Portfolio Manager at ArrowMark. “AbCellera is
the proven technology leader in the space, and with its full,
in-house drug development capabilities it can advance programs from
concept to IND-enabling studies with speed and precision.”
"Successful biotech companies are created from a special alchemy
of science, business, technology, talent, and capital,” said Carl
Hansen, Ph.D., founder and CEO of AbCellera. “Our strategic
alliance with Viking and ArrowMark brings strong relationships and
complementary strengths to a common mission — launching new
companies and creating innovative new medicines that move the
needle for patients in need."
Under the terms of the collaboration, Viking and ArrowMark will
be majority shareholders of the Newcos, and AbCellera will
participate as an equity founding partner with the potential for
milestones and royalties on future sales of each product.
About AbCellera Biologics Inc.
AbCellera (Nasdaq: ABCL) discovers and develops antibody
medicines for indications across therapeutic areas including
cancer, metabolic and endocrine conditions, and autoimmune
disorders. AbCellera’s engine integrates technology, data science,
infrastructure, and interdisciplinary teams to solve the most
challenging antibody discovery problems. AbCellera is focused on
advancing an internal pipeline of first-in-class and best-in-class
programs and collaborating on innovative drug development programs
with partners. For more information, please visit
www.abcellera.com.
About ArrowMark Partners
ArrowMark Partners is a privately held, employee-owned
investment management firm founded in 2007 and headquartered in
Denver, Colorado. Unified by a fundamental, research-driven
philosophy and integrated investment platform, we focus on niche
and less efficient market segments in public and private credit and
equity, leveraged loans, and middle-market commercial real estate
finance where our size, agility, and specialized expertise can
deliver differentiated investing outcomes for clients.
AbCellera Forward-Looking Statements
This press release contains forward-looking statements,
including statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The
forward-looking statements are based on management’s current
beliefs and assumptions and on information currently available to
management. All statements contained in this release other than
statements of historical fact are forward-looking statements,
including statements regarding our ability to develop,
commercialize, and achieve market acceptance of our current and
planned products and services, our research and development
efforts, and other matters regarding our business strategies, use
of capital, results of operations and financial position, and plans
and objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties, and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties,
and other factors are described under “Risk Factors,” “Management's
Discussion and Analysis of Financial Condition and Results of
Operations,” and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240501764172/en/
Inquiries
Media: Kathleen Reid; media@abcellera.com, +1(236)521-6774
Business Development: Murray McCutcheon, Ph.D.; bd@abcellera.com,
+1(604)559-9005 Investor Relations: Melanie Solomon;
ir@abcellera.com, +1(778)729-9116
AbCellera Biologics (NASDAQ:ABCL)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
AbCellera Biologics (NASDAQ:ABCL)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024